Company Highlights Strategic Transformation Toward Biotechnology, Regenerative Medicine and Stem Cell Technologies
[Toronto, Canada] – 20th July 2026 – Visionary Holdings Inc. (NASDAQ: GV) today announced its unaudited financial results for the first half of Fiscal 2026 and provided an update on the Company’s strategic transformation toward a biotechnology-focused business platform.
For the six months ended September 30, 2025, the Company reported revenue of approximately US$434,648 and gross profit of approximately US$283,961, representing a gross margin of 65.3%. Net loss attributable to Visionary Holdings improved to approximately US$2.0 million from approximately US$5.9 million in the prior-year period. Total assets were approximately US$65.7 million at period end.
These financial results primarily reflect the Company’s existing operations while its biotechnology initiatives remain in the strategic development stage.
During the reporting period, Visionary continued advancing its long-term corporate transformation. Management has refined the Company’s strategic focus toward biotechnology, with priority areas including stem cell technologies, regenerative medicine, anti-aging therapies and medical aesthetics. The Company is evaluating research collaborations, technology licensing opportunities, strategic investments and intellectual property development to establish an integrated biotechnology platform capable of supporting long-term growth.
While biotechnology will become the Company’s primary strategic direction, Visionary intends to continue operating its existing businesses during the transition period. Artificial intelligence and digital technologies are expected to serve as enabling technologies supporting research, operational efficiency and future precision-health applications.
“The first half of Fiscal 2026 represents an important transition period for Visionary,” management commented. “While our reported financial results continue to reflect our existing operations, we are actively repositioning the Company toward biotechnology. We believe this strategy will strengthen our long-term competitiveness and create a foundation for sustainable shareholder value through scientific innovation, strategic partnerships and disciplined execution.”
About Visionary Holdings Inc.
Visionary Holdings Inc. (NASDAQ: GV) is a Canada-based public company undertaking a strategic transformation toward biotechnology. The Company intends to focus on stem cell technologies, regenerative medicine, anti-aging therapies, medical aesthetics and related healthcare innovation while continuing to operate and optimize its existing businesses.
Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding the Company’s strategic transformation, biotechnology initiatives, future collaborations, commercialization plans and long-term growth strategy. Actual results may differ materially due to various risks and uncertainties described in the Company’s filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update these statements except as required by law.
Investor Relations
Visionary Holdings Inc.
Investor Relations
Email: [email protected]
Comments (0)